Dr Karin Hellner
|Tel||+44 (0)1865 221021|
|Fax||+44 (0)1865 769141|
Fellowships & Awards
- 2000 - 2001: PhD student fellowship by the Charite - Medical Faculty, Humboldt-University of Berlin
- 2007 - 2008: Postdoctoral Research Fellowship by the German Research Foundation (DFG) for basic research at Harvard Medical School Boston, USA
- 2010: DNA Tumor Virus Conference Grant (Travel Award)
- 2010: Brigham & Women's Hospital Peer Mentor Award
- 2015: Oxford University Clinical Academic Graduate School (OUCAGS) Career Development Grant
- 2015: OUCAGS Travel Grant for Clinical Lecturers
Biography & Research
I received my medical degree from the Humboldt-University of Berlin in 2003 and split my specialist training between the Charité - Universitätsmedizin Berlin, in Germany, and Oxford University Hospitals NHS Trust, in Oxford. I obtained my CCT in February 2015.
In 2007, I interrupted my clinical training and spent 4 years as a postdoctoral research fellow at Harvard Medical School / Brigham & Women's Hospital in Boston, USA, where I have been working on the molecular mechanisms of human papillomavirus associated carcinogenesis and drug discovery strategies for cervical cancer.
I joined the University of Oxford as a clinical lecturer in 2011 to work with Prof. Ahmed A. Ahmed at the Weatherall Institute of Molecular Medicine. My research focused on the genomic composition and evolution of ovarian tumors and their precursor lesions.
In 2015, I joined Prof. Zondervan's and Prof. Becker's EndoCaRe (Endometriosis Care and Research) team to apply my expertise in the field of reproductive disease. I was recently awarded a grant which supports my efforts to study single cell transcriptomics in endometriosis.
Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies.
Hellner K. et al, (2016), EBioMedicine
Evaluation Of the Monocyte To Lymphocyte Ratio As a Predictive Marker in Endometriosis Patients.
Hellner K. et al, (2016), REPRODUCTIVE SCIENCES, 23, 327A - 327A
Viral perturbations of host networks reflect disease etiology.
Gulbahce N. et al, (2012), PLoS Comput Biol, 8
Human papillomaviruses as therapeutic targets in human cancer.
Hellner K. and Münger K., (2011), J Clin Oncol, 29, 1785 - 1794
Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3.
Baldwin A. et al, (2010), Proc Natl Acad Sci U S A, 107, 12463 - 12468